Merck Research Laboratories, Kenilworth, NJ. Background: Asthmatics often report asthma-related nocturnal awakenings. These sleep interruptions may have a significant impact on patients' quality of life. We characterized the effect of mometasone furoate/formoterol (MF/F) administered via pressured metered-dose inhaler on incidence of nocturnal awakenings requiring short-acting b 2 -agonists (SABAs). Methods: MF/F's effect on nocturnal awakenings requiring SABA was characterized across 3 phase III efficacy trials (baseline ¼ number of nights with awakenings in week before first dose; endpoint ¼ number of nights/wk with awakenings averaged across the 26-week treatment period). Subjects were asthmatics previously treated with low-(n¼746), medium-(n¼781) or highdose (n¼728) inhaled corticosteroids at various doses. Subjects in the MF/F 100/10 mg BID study were randomized to 26 weeks of twice-daily (BID) treatment with MF/F 100/10 mg, MF 100 mg, F 10 mg, or placebo; subjects in the MF/F 200/10 mg BID study to 26 weeks of BID treatment with MF/F 200/ 10 mg, MF 200 mg, F 10 mg, or placebo; and subjects in the MF/F 400/10 mg BID study to 12 weeks of BID treatment with MF/F 400/10 mg, MF/F 200/10 mg, or MF 400 mg. All treatments were delivered via a metered dose inhaler. Results: Baseline awakenings ranged from 0.84-1.05, 1.05-1.26, and 1.33-1.61 nights/wk in the MF/F 100/10 mg BID, MF/F 200/10 mg BID, and MF/F 400/10 mg BID studies, respectively. In the MF/F 100/10 mg BID study, nocturnal awakenings were reduced by MF/F ¼ -0.42, MF ¼ -0.21, F ¼ -0.21, and placebo ¼ 0.14 nights/wk; corresponding changes in the MF/F 200/10 mg BID study were -0.56, -0.35, 10.07 and 0.00 nights/wk, respectively. In each of these placebo-controlled studies, MF/F was superior to placebo (P , .001) and F (P #.035); MF was also superior to F and placebo. In the MF/F 400/10 mg BID study, awakenings were reduced by -0.70, -0.70 and -0.35 nights/wk by MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg, respectively; both MF/F treatments were superior to MF (P #0.006). Conclusions: These results provide evidence that validates the role of MF/F in reducing nocturnal asthma symptoms in patients with moderate to severe persistent asthma and supports the efficacy of MF/F compared with that of placebo and F. Background: A major goal of asthma treatment is to improve patients' health-related quality of life (QoL). Mometasone furoate/formoterol (MF/F) combination therapy was recently approved for the treatment of persistent asthma. The objective of this analysis was to examine the effect of MF/F on health-related QoL at the approved doses. Methods: Data from 2 phase III studies investigating the effects of MF/F 200/ 10 mg (study P04334) and MF/F 400/10 mg (study P04431) were included. All subjects were $12 yeara and not well controlled on medium dose (P04334) or high-dose (P04431) inhaled corticosteroid (ICS). After 2 to 3 weeks of run-in on twice-daily (BID) MF 200 mg (P04334) or 400 mg (P04431), subjects were randomized to 26 weeks of BID MF/F 200/10 mg, MF 200 mg, F 10 mg, or placebo (PBO) in P04334; or 12 weeks of BID MF/F 200/10 mg, MF/F 400/10 mg, or MF 400 mg in P04431. The Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ [S]), consisting of 4 domains (Symptoms, Activity Limitation, Emotional Function, and Environmental Stimuli), was used to assess QoL. AQLQ(S) score changes from baseline were assessed; a difference $0.5 was considered clinically meaningful. Study protocols were approved by IRBs; written informed consent was provided by all subjects or a parent/guardian. Results: In P04334 (n ¼ 781), subjects receiving MF/F 200/10mg experienced significant improvements in total score (13.1%) and the 4 domain scores of the AQLQ (S) at endpoint vs those receiving PBO (P # 0.005) or F 10 mg (P # 0.024). Clinically meaningful improvements in total AQLQ (S) from baseline to week 26 were observed in patients receiving MF/F 200/ 10 mg (0.61). In P04431 (n ¼ 728), subjects receiving MF/F 200/10 mg experienced significant improvements in total score (12.8%) and the Symptoms and Activity Limitation domain scores of the AQLQ (S) at endpoint vs those who received MF 400 mg (P # 0.017). Clinically meaningful improvements in total AQLQ (S) from baseline to week 12 occurred in patients receiving MF/F 200/10 mg (0.61), MF/F 400/10 mg (0.51), or MF 400 mg (0.5). Conclusions: Patients with persistent asthma receiving MF/F had statistically significant, clinically meaningful improvements in QoL in 2 phase III studies. These data suggest that MF/F combination therapy improves the healthrelated QoL of patients with persistent asthma who are inadequately controlled on medium-or high-dose ICS. Background: Asthma is a variable disease. Optimal control in clinical practice often requires the use of therapy at varying doses. Availability of treatments at multiple strengths is therefore essential. These are results from a 6-month trial of combined mometasone furoate/formoterol (MF/F) 100/10 mg administered via a metered-dose inhaler (MDI) as treatment for asthma deterioration (ie, severe asthma exacerbation) and bronchoconstriction in asthmatics previously treated with low-dose inhaled corticosteroids (ICS). Methods: In a randomized, multicenter, double-blind, placebo-controlled study in asthma subjects ($12 years) on ICS with/without a long-acting b 2 -agonist (LABA), subjects were assigned to 2 to 3 weeks of open-label MF 100 twice daily (BID), followed by 26 weeks of MF/F 100/10 mg, MF 100 F 10 or placebo (all BID). Co-primary endpoints were time to first asthma deterioration across the 26-week treatment period (MF/F versus F) and change from baseline to week 12 in serial (0212 hours) forced expiratory volume in 1 second (FEV 1 ) (MF/F vs MF). Adverse events (AEs) were monitored. 
